Suscribirse

Prospects for Leveling the Playing Field for Black Children With Autism - 29/08/23

Doi : 10.1016/j.jaac.2023.05.005 
John N. Constantino, MD a, ⁎ , Anna M. Abbacchi, MS b, Brandon K. May, PhD, MSW, BCBA-D b, Cheryl Klaiman, PhD c, Yi Zhang, MS b, Jennifer K. Lowe, PhD d, Natasha Marrus, MD, PhD b, Ami Klin, PhD c, Daniel H. Geschwind, MD, PhD d
a Emory University School of Medicine, Atlanta Georgia 
b Washington University School of Medicine, St. Louis, Missouri 
c Marcus Autism Center, School of Medicine, Emory University, Atlanta, Georgia 
d David Geffen School of Medicine, University of California, Los Angeles, California 

∗Correspondence to John N. Constantino, MD, Emory University School of Medicine, 1575 Northeast Expressway NE, Support Building II, E290, Atlanta, GA 30329Emory University School of Medicine1575 Northeast Expressway NESupport Building IIE290AtlantaGA30329

Resumen

Among the many race-based health disparities that have persistently plagued the US population,1 the disproportionate burden of adverse neurodevelopmental outcomes to Black children affected by autism spectrum disorder (ASD) is particularly devastating given its major lifelong consequences. Recently, in 3 successive reports from the Autism and Developmental Disabilities Monitoring (ADDM) program of the US Centers for Disease Control and Prevention (CDC) (birth cohort years 2014, 2016, and 2018), we and our collaborators reported that although the prevalence of community-diagnosed ASD had equalized for Black and non-Hispanic White (NHW) children in the United States, there has persisted a pronounced racial disparity in the proportion of ASD-affected children with comorbid intellectual disability (ID), on the order of 50% for Black children with ASD vs 20% for White children with ASD.2 Here, we provide data to support the following: much earlier diagnosis is possible; early diagnosis alone is not likely to close the ID comorbidity disparity; and judicious efforts over care as usual are necessary to ensure that Black children have access to timely implementation of developmental therapy, for which we observed promising associations with improved cognitive and adaptive outcomes in our sample.

El texto completo de este artículo está disponible en PDF.

Esquema


 Dr. Constantino and Ms. Abbacchi contributed equally to this work.
 This work was made possible by National Institutes of Health (NIH) Grant R01 MH100027 (Daniel H. Geschwind, P.I.), NIH Grant P50 HD103525 (John N. Constantino, P.I.), and a gift from the Steward Family Foundation to Washington University.
 This article is part of a special series devoted to addressing bias, bigotry, racism, and mental health disparities through research, practice, and policy. The series is edited by Assistant Editor Eraka Bath, MD, Deputy Editor Wanjikũ F.M. Njoroge, Associate Editor Robert R. Althoff, MD, PhD, and Editor-in-Chief Douglas K. Novins, MD.
 Author Contributions
Conceptualization: Constantino, Abbacchi, Lowe, Marrus, Klin, Geschwind
Data curation: Constantino
Formal analysis: Constantino, Abbacchi, Klaiman, Zhang
Funding acquisition: Constantino, Klin, Geschwind
Investigation: Constantino, Abbacchi, Klin, Geschwind
Methodology: Constantino, Abbacchi, May, Klaiman, Lowe, Klin, Geschwind
Project administration: Constantino, Abbacchi, May, Klaiman, Lowe
Resources: Constantino
Software: Constantino
Supervision: Constantino, Abbacchi, May, Klaiman, Lowe, Klin, Geschwind
Validation: Constantino
Visualization: Constantino
Writing – original draft: Constantino, Abbacchi, May, Klaiman
Writing – review and editing: Constantino, Abbacchi, Lowe, Marrus, Klin, Geschwind
 The authors gratefully acknowledge the commitment of the participating families to promote and ensure equity in the science and clinical treatment of autism spectrum disorder (ASD) and the support of clinical diagnostic and intervention planning efforts in St. Louis made possible through the Waitlist Reduction and Training Services program of the Missouri Department of Mental Health.
 Disclosure: Dr. Constantino has received royalties from Western Psychological Services for the commercial distribution of the Social Responsiveness Scale (SRS-2). Dr. Klin is inventor of technologies deployed by EarliTec Diagnostics, Inc., of which he is an equity holder. EarliTec is a company that develops medical devices for early diagnosis of ASD and gives a portion of its revenue to support treatment of children with ASD. Drs. May, Klaiman, Lowe, Marrus, and Geschwind and Mss. Abbacchi and Zhang have reported no biomedical financial interests or potential conflicts of interest.
 All statements expressed in this column are those of the authors and do not reflect the opinions of the Journal of the American Academy of Child and Adolescent Psychiatry. See the Guide for Authors for information about the preparation and submission of Letters to the Editor.


© 2023  American Academy of Child and Adolescent Psychiatry. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 62 - N° 9

P. 949-952 - septembre 2023 Regresar al número
Artículo precedente Artículo precedente
  • Meeting Youth Where They Live: How to Use a QR Code in Safety Planning
  • Thomas Zimmer, Paresh Patel
| Artículo siguiente Artículo siguiente
  • Using Technology to Limit the Impacts of Isolation on Youth in Inpatient Psychiatry Units
  • Kaitlin Hanss, Rebecca Carcana, Timothy Rice

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.